Navigation Links
BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008
Date:1/31/2008

he pivotal U.S. clinical study and leading dermatologists' long-term clinical experience with RADIESSE filler, also demonstrating safety of RADIESSE filler in clinical use and high patient satisfaction.

The results of these studies were published in the December 2007 and February 2008 issues of the Journal of Dermatologic Surgery, a peer-reviewed publication of the American Society of Dermatologic Surgery. The Company believes that the aesthetic outcomes highlighted in these publications are key factors that have and will continue to contribute to the growing adoption of RADIESSE filler in physician practices.

Fiscal Year 2008 Revenue Guidance:

BioForm Medical is updating its revenue guidance for the full fiscal year 2008 ending June 30, 2008 to approximately $71 to $76 million of net sales.

Conference Call:

BioForm Medical will hold a conference call today at 2:00 pm Pacific Time (5:00 p.m. Eastern Time) to discuss the financial results and guidance. The conference call will be webcast live on the Investor Relations section of BioForm Medical's website at http://www.bioform.com. The conference call may be accessed by dialing 888-670-2248 for callers in the U.S. and 913-905-3226 for international callers. Please notify the operator that you would like to join "BioForm Medical's Second Quarter Earnings Call" and provide the participant code "7132314", if prompted.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm Medical is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm Medical's products include Radiesse(R) dermal filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) injectable implant for treating female stress urinary incontinence which is marketed through a par
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. BioForm to Announce First Quarter Fiscal 2008 Financial Results and Host Conference Call and Webcast on December 13, 2007
2. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
3. AMERIGROUP Foundation Announces Winners of Word About Health Contest
4. Cardinal Health Announces Resignation of Director; Declares Regular Quarterly Dividend
5. Horace Mann Announces Fourth Quarter Earnings Release and Conference Call
6. MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System
7. MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012
8. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
9. Webcast Alert: HCA Announces 4Q-Year End 07 Earnings Report
10. Pennsylvania Governor Rendell Announces $1.8 Million Investment to Add Nurses, Improve Nurse Education Grants Awarded to Recipients in 28 Counties
11. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ivors of testicular cancer who were treated with c...ffects, including neurological side effects and Ra...d with chemotherapy, according to a new study publ...tional Cancer Institute . , Marianne Brydy, M.D....ity Hospital, in Bergen, Norway, and colleagues co...
(Date:11/25/2009)...-up period was too short to draw definite conclusi...5 (HealthDay News) -- In diabetic patients with bl...fference in outcomes at one year whether patients ...g, British researchers report. , Bypass surgery...ents with coronary artery disease. However, less i...
(Date:11/25/2009)...plagued by neurological symptoms, study finds , ...Neurological side effects are among the potential ...r cancer who were treated with cisplatin-based che...ncluded 1,409 Norwegian men treated for unilateral...part in a follow-up survey conducted from 1998 to ...
(Date:11/25/2009)...ImprovementShownforthe4thStraightYear ,, WASH...CancerAlliance-Georgia(LCA-GA)issuedthe 4thAnnualR...rogressbeingmadeagainstthislethaldiseaseinthestate...),theonlynationalorganizationdedicatedexclusivelyt...iskforlungcancer. ,, (Logo: http://www.newscom....
(Date:11/25/2009)...laced under the skin kill tumor cells, study finds... -- A cancer vaccine delivered in a fingernail-siz...w study reports. , The method uses polymer disk...th tumor-specific antigens and implanted under the...ors. The Harvard University scientists who develop...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
...d a closely monitored surveillance for patients wi...he occurrence of cancer recurrence // compared to ...most of the hospitals. Researchers have found that... treatment and cancer survival. Researchers...
...ghanistan and Nigeria is a polio-endemic country, ...o stop the indigenous polio transmission, accordin...rget remaining strains of the virus has also been ..., namely poliovirus types 1 and 3.In 2006, monoval...
...couraging people from Hong Kong from buying poultr...raditional dish consumed during the // ar New Year...er said Hong Kong residents would ask vendors to k...three from a village in the Shataukok border area ...
...are coming to India for the sake of low priced cos...ucing the waistline, rhinoplasty, and breast impro...osmetic surgeries are conducted in the UK every ye...ic operations performed in 2005. Each breast enlar...
...adversely affected as a result of snoring, accordi...ders Center at Rush University Medical Center // i...the snoring of their husbands. This problem has al...ween the couple when one of them is deprived of sl...
...arch is on the verge of path breaking news that s...cy and schizophrenia. // Reduced vitamin D leve... could spark off the onset of this disorder, acco...el this potential link between Schizophrenia and V...
Other Medicine News:Health News:More People Come To India For Cosmetic Surgery 2Health News:Sunny Side Up - Vitamin-D deficiency linked to Schizophrenia 2
(Date:11/25/2009)...25/PRNewswire/--TheFDAgrantedtraditionalapprovalfo...ereversetranscriptaseinhibitor(NNRTI).INTELENCEist...experiencedadultswhoareexperiencingvirologicfailur...roviral(ARV)agents.Thetraditionalapprovalisbasedon...T-2.INTELENCEiscurrentlymarketedintheU.S.byTibotec...
(Date:11/25/2009)....25/PRNewswire/--RegadoBiosciences,aprivatelyheldc...swithactivecontrolagents,announcedthatDavidMazzo,P...ay21stAnnualHealthCareConferenceattheNewYorkPalace...enat1:10pm(EST)onTuesday,December1andwillincludean...ddevelopmentprogram,theanticoagulantsystem,REG1.Th...
(Date:11/25/2009)...25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX...rebloodanalysissystems,announcedtodaythatClintSeve...tthe21stAnnualPiperJaffrayHealthCareConferenceonWe...llbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...ndmarketsportablebloodanalysissystemsforuseinanyve...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation 5646 1HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation 5646 2Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day 5643 1Lilly Surpasses Energy Efficiency Goals and Celebrates Worldwide Energy Day 5643 2NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 1NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 2NGM Biopharmaceuticals Appoints Dr Arthur D Levinson Former Genentech CEO to its Board of Directors 5640 3
...ical data for potential combination,therapies and ...r,ITMN-191 exposure, BARCELONA, Spain, April 11, 2...unced today the presentation of findings from,thre... inhibitor,ITMN-191, alone or in combination with ... European Association for the Study of the,Liver i...
...IRE)--Apr 11, 2007 - New data,supporting the clini... most advanced investigational oral protease inhib... infection, will be presented,at the 42nd Annual M...f the Liver (EASL) in Barcelona this week. In tota...accepted for presentation,at the EASL conference, ...
Other Medicine Technology:InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6
LD Lactate –> Pyruvate
Rheumatoid Factor Latex Test (RF)
IgG (sample dilution, 1-shot only) (Liquid)
CRP (Complete Kit with Disposible Cards)
Medicine Products: